Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Plasma HIV-1 RNA ≥ 500 copies/mL at screening Visit~* Currently taking a failing ARV regimen that contains 2 NRTIs and a NNRTI~* No prior or current ARV regimens containing integrase inhibitor (INSTI) or protease inhibitor (PI)~* Screening genotype must show at least the protocol defined resistance mutation profile~Key Exclusion Criteria:~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Day 1~* Participation in any other clinical trial, including observational studies, without prior approval from the sponsor is prohibited while participating in this trial~* Use of an investigational drug other than the study drug~* Individuals with chronic hepatitis B virus (HBV) infection are not permitted to participate~* Active tuberculosis infection~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1 Sentinel Cohort 1: GS-9131 60 mg (Type: EXPERIMENTAL): Treatment experienced participants will receive GS-9131 60 mg in addition to their current failing ARV regimen for a period of 10 days.
- Part 1 Sentinel Cohort 2: GS-9131 180 mg (Type: EXPERIMENTAL): Treatment experienced participants will receive GS-9131 180 mg in addition to their current failing ARV regimen for a period of 14 days.
- Part 1: Randomized Cohort (Type: EXPERIMENTAL): Participants will be randomized in 1:1:1:1 so as to receive GS-9131 in 3 active dose levels up to a maximum of 180 mg or Placebo to match GS-9131 in addition to their current failing ARV regimen for a period of 14 days in Part 1.
- Part 2 Sentinel Cohort 1: GS-9131 + BIC + DRV + RTV (Type: EXPERIMENTAL): Participants who complete dosing in Sentinel Cohort 1 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 11 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 60 mg + bictegravir (BIC) 30 mg + darunavir (DRV) 800 mg + ritonavir (RTV) 100 mg for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 60 mg + BIC 75 mg + tenofovir alafenamide (TAF) 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.
- Part 2 Sentinel Cohort 2: GS-9131 + BIC + TAF (Type: EXPERIMENTAL): Participants who complete dosing in Sentinel Cohort 2 of Part 1 and show a reduction in plasma HIV RNA \> 0.5 log10 from their pre-GS-9131 baseline value at Day 15 and discontinue their current failing regimen will receive an optimized regimen consisting of GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for a period of 24 weeks. After Week 24, participants will be given the option to participate in an open label extension and receive GS-9131 180 mg + BIC 75 mg + TAF 25 mg, for an additional 24 weeks or until Gilead Sciences elects to discontinue the study drug in that country, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy